HUYA Bioscience is partnering with the Beijing Institute of Materia Medica (BIMM) on preclinical safety and efficacy activities as well as clinical trial protocols. The agreement also provides HUYA with the right of first review and negotiation for the licensing and development of certain new compounds owned or controlled by BIMM. This right includes drugs for cardiology, endocrinology, oncology, immunology, hematology, neuroscience, and infectious diseases.
BIMM comprises the Chinese Academy of Medical Sciences and Peking Union Medical College. It concentrates on discovering and developing treatments by isolating natural remedies. “For BIMM,” says Xiaoling Wang, M.D., Ph.D., BIMM director, “our partnership with HUYA signifies an opportunity to bring our expertise and our efforts in pharmaceutical development to the Western market.”
HUYA CEO, Mireille Gingras, Ph.D., adds that, “HUYA is highly experienced and uniquely positioned in China to leverage the emerging biotech industry through strong collaborations. This is the culmination of years of relationship-building and exchange of knowledge between HUYA and BIMM.”
To comment on this story, go to BLOGbiotech.